checkAd
    Startseite > Aktien > Tevogen Bio Holdings > Nachrichten
    Tevogen Bio Holdings Aktie
    0,8200
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 25.05.24 NYSE
    0,7586
     
    USD
    100 STK
    Geldkurs 24.05.24
    0,8200
     
    USD
    200 STK
    Briefkurs 24.05.24
    ISIN: US88165K1016 · WKN: A402TW · SYM: TVGN · USA

    Neueste Nachrichten

    Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
    16.05.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
    10.05.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
    01.05.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
    26.04.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
    11.04.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
    03.04.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
    28.03.24 · globenewswire · Tevogen Bio Holdings
    Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
    20.03.24 · Business Wire (engl.) · Tevogen Bio Holdings
    Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
    05.03.24 · Business Wire (engl.) · Tevogen Bio Holdings
    Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI
    27.02.24 · Business Wire (engl.) · Tevogen Bio Holdings
    Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
    21.02.24 · Business Wire (engl.) · Tevogen Bio Holdings
    Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
    17.02.24 · Business Wire (engl.) · Tevogen Bio Holdings